• Investment Books

  
  

• Smart Investment

  

Drug maker Sun Pharmaceutical Industries announced that the company along with its subsidiaries had received final approval from US Food and Drug Administration (USFDA) for  several abbreviated new drug applications (ANDA).

Approval was received for generic hydocodone bitarlate with acetaminophen (APAP) tablets. Approval was also received for generic `Aredia`, paamidronate disodium for injection USP, generic Lopid, gemfibrozil tablets, USP and promethazine hydrochloride tablets.

The approvals for the hydocodone with APAP are the first approvals for products based on controlled substances, the company disclosed. Hydocodone with APAP is a narcotic analgesic indicated in the treatment of relief of moderate to moderately severe pain of acute, chronic or post-operative types.

-IRIS.

Tags:abbreviated new drug applications (ANDA), ANDA, APAP, Drug maker Sun Pharmaceutical Industries, Gemfibrozil tablets, generic Lopid, Indian Stock Market News, injection USP, promethazine hydrochloride tablets, Stock Market News, Sun Pharma, Sun Pharmaceutical Industries, US Food and Drug Administration (USFDA), USFDA, USP

Related Post :

• Sun Pharma’s arm gets USFDA nod
• Sun Pharma arm gets USFDA nod
• Sun Pharma gets FDA nod for generic Roxicodone
• Sun Pharma gets FDA approval for topiramate
• Indian pharma companies bullish in the US
• Glenmark | Glenmark gets USFDA nod for hypertension tablets
• Jubilant Organosys arm gets USFDA nod for Draximage’s Sestamibi
• Glenmark arm gets tentative USFDA nod

• Search

• Investment Books

  
  

• Smart Investment